Newsable Asianet News on MSN
Mounjaro Vs Trulicity: Eli Lilly’s New FDA Win Puts Its Blockbuster Weight-Loss Drug In Focus
Mounjaro produced an 8% lower rate of cardiovascular death, heart attack or stroke than Lilly’s diabetes drug Trulicity.
Zacks Investment Research on MSN
LLY's Mounjaro gets FDA nod to cut cardiovascular risk in diabetes
The FDA has approved Eli Lilly’s LLY Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type II diabetes ...
Trulicity helps lower blood sugar in adults and children ages 10 years and older with type 2 diabetes. It also may reduce major heart risks in adults with type 2 diabetes who have or are at risk for ...
Everyday Health on MSN
GLP-1 Diabetes Drug Mounjaro Gets FDA Okay to Reduce Heart Attack and Stroke
Research shows this tirzepatide GLP-1/GIP medication may help prevent cardiovascular emergencies in high-risk type 2 diabetes ...
On Aug. 28, the U.S. Food and Drug Administration (FDA) approved Mounjaro to lower the risk of heart events, including heart ...
Renée Fabian is Lead Editor for Pet Health at Forbes Advisor. She has over 10 years experience as a journalist and editor covering pet and human health topics. Renée previously worked as senior pet ...
SAN FRANCISCO—Back in November, news of a cardiovascular outcomes win for Trulicity pleased Eli Lilly investors whom analysts called “skeptical.” Now, those same skeptics may wonder just how well ...
INDIANAPOLIS, June 13, 2020 /PRNewswire/ -- New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide ...
New indication reflects distinct patient population in the REWIND study, including primarily people with multiple cardiovascular risk factors but without established cardiovascular disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results